Skip to main content
Normal View

Wednesday, 6 Jul 2016

Written Answers Nos. 220-227

Medical Products

Questions (220)

Billy Kelleher

Question:

220. Deputy Billy Kelleher asked the Minister for Health why University Hospital Limerick is effectively denying compassionate access to orkambi for very ill patients in contrast to other cystic fibrosis hospitals; why very ill patients are being denied an available and free therapy; why has the Health Service Executive provided no explanation for this to Cystic Fibrosis Ireland, despite repeated efforts on the latter's part; why is University Hospital Limerick in apparent contravention of the Minister where he has urged compassionate use of particular drugs for cancer; why the hospital is saying the drug can be provided from a community pharmacy when the executive states that this is not possible and given that hospital pharmacies are facilitating compassionate use of orkambi in Cork and in St. Vincent’s Hospital and Crumlin Hospital in Dublin; and if he will make a statement on the matter. [19964/16]

View answer

Written answers

As this is a service matter, I have asked the HSE to respond to you directly. If you have not received a reply from the HSE within 15 working days please contact my Private Office and my officials will follow the matter up.

Hospital Appointments Status

Questions (221)

Billy Kelleher

Question:

221. Deputy Billy Kelleher asked the Minister for Health the status of an appointment for a person (details supplied); and if he will make a statement on the matter. [19967/16]

View answer

Written answers

As this is a service issue, this question has been referred to the Health Service Executive for direct reply to the Deputy. If you have not received a reply from the HSE within 15 working days, please contact my Private Office and they will follow up the matter with them.

Health Services

Questions (222)

Fergus O'Dowd

Question:

222. Deputy Fergus O'Dowd asked the Minister for Health to review an application by a person (details supplied) for a transfer; and if he will make a statement on the matter. [19973/16]

View answer

Written answers

I have asked the HSE to respond to the Deputy directly on this matter. If you have not received a reply from the HSE within 15 working days please contact my Private Office and they will follow up the matter with them.

Pension Provisions

Questions (223)

Billy Kelleher

Question:

223. Deputy Billy Kelleher asked the Minister for Health the status of an application by a person (details supplied) for a pension; and if he will make a statement on the matter. [19982/16]

View answer

Written answers

I have asked the HSE to respond to the Deputy directly on this matter. If you have not received a reply from the HSE within 15 working days please contact my Private Office and they will follow up the matter with them.

Rare Diseases

Questions (224)

Tom Neville

Question:

224. Deputy Tom Neville asked the Minister for Health his views on correspondence (details supplied) regarding an exomphalos day; and if he will make a statement on the matter. [19986/16]

View answer

Written answers

Exomphalos is considered to be a rare disease. There are approximately 8,000 rare diseases and Rare Disease Day is celebrated across Europe at the end of February every year. This day also has the support of the European Union and the day promotes awareness of a range of rare diseases.

Health Services Staff

Questions (225)

Michael Healy-Rae

Question:

225. Deputy Michael Healy-Rae asked the Minister for Health his views on correspondence (details supplied) regarding physical therapists; and if he will make a statement on the matter. [19998/16]

View answer

Written answers

Protection of title is a core function of the Health and Social Care Professionals Council and the registration boards established under the Health and Social Care Professionals Act 2005. It is vital that when people access the health services that there is no ambiguity in relation to the profession and the competence of the health service provider that they are attending.

The Physiotherapists Registration Board is currently preparing the necessary bye-laws under the Act to allow it to establish its register in the coming months. The title of physiotherapist will, as a consequence, be protected under the Act for the exclusive use of the board's registrants when the register's 2-year transitional period ends in 2018.

Last year, my predecessor, Leo Varadkar TD, consulted with the Physiotherapists Registration Board and thereafter wrote to a number of relevant organisations about the question of also protecting the title of physical therapist under the Act.

He came to the conclusion that prescribing the title of physical therapist under the Act as a variant of the title of physiotherapist would be the best way to eliminate the ongoing risk of title confusion and the consequent risks to public safety.

He also decided to allow existing users of the title physical therapist who are not physiotherapists but who hold qualifications of a certain standard to continue to use the title. New grand parenting provisions will allow such practitioners to apply, on a once-off basis and for a limited period, to register in the physiotherapists register. After this period only qualified physiotherapists will be permitted to register.

The registration board's code of professional conduct and ethics will ensure that all registrants, including those registered under the new provisions, act within the limits of their knowledge, skills, competence and experience.

My Department is preparing the necessary legislation to give effect to the decisions which have been communicated to the Physiotherapists Registration Board and other interested parties.

Medical Products

Questions (226)

Billy Kelleher

Question:

226. Deputy Billy Kelleher asked the Minister for Health his position on the introduction of the drug Ampligen for the treatment of multiple myalgic encephalopathy; and if he will make a statement on the matter. [20029/16]

View answer

Written answers

Rintatolimod (brand name Ampligen) is an experimental drug in development for the treatment of a variety of chronic diseases and viral disorders, including Chronic Fatigue Syndrome or Myalgic Encephalomyelitis (ME).

The drug has not been authorised by the European Medicines Agency for the treatment of ME in the European Union. If the drug should receive marketing authorisation in Ireland, it would then be open to the marketing authorisation holder to make the drug available for prescribing, and to apply to the HSE to have the product reimbursed under the State drugs schemes.

I understand that the U.S. Food and Drug Administration (FDA) has declined to approve rintatolimod for use in the U.S., despite conducting several reviews of the drug over the last decade.

Hospital Waiting Lists

Questions (227)

Fergus O'Dowd

Question:

227. Deputy Fergus O'Dowd asked the Minister for Health the number of persons on the waiting list, the average waiting time and the number of persons waiting over six months for laser treatment of kidney stones in County Louth; and if he will make a statement on the matter. [20045/16]

View answer

Written answers

As this is a service matter, I have asked the HSE to respond to you directly. If you have not received a reply from the HSE within 15 working days please contact my Private Office and my officials will follow the matter up.

Top
Share